Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Claritin-D

This article was originally published in The Tan Sheet

Executive Summary

Andrx receives tentative FDA approval July 9 for 24-hour loratadine/pseudoephedrine combination. Generics company is believed to be first to file an ANDA for equivalent to Schering-Plough's Claritin-D 24-Hour; Impax Labs was first to file for 12-hour formulation and has entered into contract manufacturing, supply agreement with Schering for OTC distribution (1"The Tan Sheet" July 1, 2002, p. 4). Andrx, Impax are defendants in Schering's ongoing patent litigation. Separately, Schering announces July 8 approval in Japan for Rx sale of Claritin 10 mg tablets...
Advertisement

Related Content

Claritin in Japan
Impax, Schering Patent Litigation Continues Despite Claritin-D Agreement
Impax, Schering Patent Litigation Continues Despite Claritin-D Agreement

Topics

Advertisement
UsernamePublicRestriction

Register

PS094271

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel